These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15154001)

  • 1. Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.
    Lopez LM; Wassef AA; Molloy MS; Williams NG
    Neuropsychopharmacology; 2004 Jun; 29(6):1217; author reply 1218-20. PubMed ID: 15154001
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical review of GABA-ergic drugs in the treatment of schizophrenia.
    Wassef AA; Dott SG; Harris A; Brown A; O'Boyle M; Meyer WJ; Rose RM
    J Clin Psychopharmacol; 1999 Jun; 19(3):222-32. PubMed ID: 10350028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targets in GABAergic neurons to treat schizophrenia.
    Costa E; Dong E; Grayson DR; Ruzicka WB; Simonini MV; Veldic M; Guidotti A
    Adv Pharmacol; 2006; 54():95-117. PubMed ID: 17175812
    [No Abstract]   [Full Text] [Related]  

  • 4. [The neuroprotective effect of GABA-ergic substances in cerebral ischemia].
    Kulinskiĭ VI; Mikhel'son GV
    Eksp Klin Farmakol; 1997; 60(1):56-8. PubMed ID: 9162288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate and the symptomatic treatment of schizophrenia spectrum patients.
    Winterer G; Hermann WM
    Pharmacopsychiatry; 2000 Sep; 33(5):182-8. PubMed ID: 11071020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents.
    Sotoing Taïwe G; Ngo Bum E; Talla E; Dawe A; Okomolo Moto FC; Temkou Ngoupaye G; Sidiki N; Dabole B; Djomeni Dzeufiet PD; Dimo T; De Waard M
    J Ethnopharmacol; 2012 Aug; 143(1):213-20. PubMed ID: 22750453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stiff-man syndrome].
    Sakai K
    Ryoikibetsu Shokogun Shirizu; 2000; (31):59-61. PubMed ID: 11269172
    [No Abstract]   [Full Text] [Related]  

  • 8. Valproate and GABAergic system effects.
    Winterer G
    Neuropsychopharmacology; 2003 Nov; 28(11):2050-1. PubMed ID: 14574363
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia.
    Larrison AL; Babin SL; Xing Y; Patel SS; Wassef AA; Sereno AB
    Hum Psychopharmacol; 2011 Oct; 26(7):517-25. PubMed ID: 22031266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular GABA in globus pallidus increases during the induction of oral tremor by haloperidol but not by muscarinic receptor stimulation.
    Collins-Praino LE; Podurgiel SJ; Kovner R; Randall PA; Salamone JD
    Behav Brain Res; 2012 Sep; 234(1):129-35. PubMed ID: 22728308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural fluid eosinophilia with combined pharmacotherapy.
    Chiles C; van Wattum PJ
    Psychosomatics; 2003; 44(5):436-7. PubMed ID: 12954922
    [No Abstract]   [Full Text] [Related]  

  • 14. Neurostabilizers for migraine prevention. From dosage administration to patient expectations.
    Wright W
    Adv Nurse Pract; 2007 Feb; 15(2):52-4, 56-8, 85. PubMed ID: 19998927
    [No Abstract]   [Full Text] [Related]  

  • 15. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of haloperidol on CSF glutamate levels in drug-naive schizophrenic patients.
    Labarca R; Silva H; Jerez S; Ruiz A; Renterías P; Ogalde C; Bustos G
    Schizophr Res; 1995 Jul; 16(1):83-5. PubMed ID: 7547651
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neurochemical aspects and pharmacological implications in essential tremor (preliminary note)].
    Piccoli F; Smorto MP; Raimondo D; Fierro B; Vinci GG; Lupo I; Pastore L; Daniele O
    Acta Neurol (Napoli); 1977; 32(4):473-80. PubMed ID: 333871
    [No Abstract]   [Full Text] [Related]  

  • 19. Electroconvulsive therapy-induced migraine successfully treated with valproic acid.
    Rovers JM; Roks G
    J ECT; 2012 Mar; 28(1):64-5. PubMed ID: 22343586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of gamma-aminobutyric acid (GABA)-elevating agents on the neuroleptic-induced activation of striatal tyrosine-hydroxylase: evidence that di-n-propylacetate augments GABAergic neurotransmission.
    Casu M; Gale K
    J Pharmacol Exp Ther; 1981 Apr; 217(1):177-80. PubMed ID: 6110774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.